Skip to main content

European Prevention of Alzheimer’s Dementia Consortium

Objective

Background:
The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infrastructure to make correct observations regarding an intervention’s value as an agent for secondary prevention. All this must exist in the right ethical, legal and social context. It must also be sustainable by being of value to numerous partners and stakeholders in the long term. The EPAD Consortium has been carefully designed to achieve the aim of secondary prevention of Alzheimer’s dementia.
Current and recent drug development programmes in AD have been limited through the collection of heterogeneous samples of patients with advanced brain disease and an inability to measure effectively an index of disease course modification.
Recruiting participants from clinics and the community for AD prevention trials with limited clinical background is both a risky and cost-inefficient strategy. Creating a disease register of people consented to enter secondary prevention trials delivers a degree of readiness that ensures better knowledge of a participants suitability and a more rapid throughput of screening for the trials. The EPAD Consortium has the necessary reach and influence from its partners to develop such a ‘readiness’ cohort.
By delivering an earlier, risk stratified population with run-in data in the EPAD Cohort across both clinical and biological domains; we can ensure a more homogenous population for study. We can also track changes in disease status as the basis for deciding on an intervention or combination of interventions likelihood of success in larger Phase 3 confirmatory trials.
Most of the scientific community still consider A dysregulation as central to AD so targeting this pathological process is a rational first step in what will be a standing trial. Other disease processes can be targeted when candidate interventions and intermediate phenotypes to reflect success are available.
EPAD High Level Structure:
The IMI-EPAD Consortium will form the third part to a proposed IMI–AD Platform (with IMI-EMIF-AD and IMI-Aetionomy) to produce a globally important superstructure for the secondary prevention of Alzheimer’s dementia.
IMI-EPAD brings together all the major cohorts in Europe purposed for the exploration of disease processes and risks for dementia. In drawing from over 40 cohorts with almost 250,000 participants in 11 countries we have the basis for the EPAD Register from which we can draw the EPAD Cohort. Expertise in basic neurodegenerative sciences, epidemiology, statistics and trial design ensures that the standing proof of concept adaptive trial will have the optimal chance of delivering meaningful and definitive answers on an interventions likely success in confirmatory trials.
In establishing the International Scientific Synergy Group (ISSG) we have ensured that our work is visible to similar international initiatives and vice versa hence, through pooling know how and sharing data we can collectively overcome this devastating global disease.
EPAD Work Packages and National Leadership:
We have created 8 work packages with 4 of these bound together in the EPAD Delivery Cluster which includes the scientific bedrock (WP1), the statistical engine room (WP2), the aggregation of suitable subjects (WP3) and trial delivery (WP4). These trial delivery activities are supported by project management (WP5), dissemination (WP6), business model and sustainability (WP7) and ethics, legal and social implications (WP8). All WPs are tightly integrated with the EPAD Steering Committee with inter-dependencies tightly managed.
This structure will ensure optimal candidate selection and trial delivery by way of creating

Call for proposal

IMI-JU-11-2013
See other projects for this call

Coordinator

JANSSEN PHARMACEUTICA NV
Address
Turnhoutseweg 30
2340 Beerse
Belgium

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Principal investigator
Serge Van Der Geyten (Dr.)
Administrative Contact
Hendrik Sipma (Dr.)

Participants (38)

THE UNIVERSITY OF EDINBURGH
United Kingdom
EU contribution
€ 4 654 552
Address
Old College, South Bridge
EH8 9YL Edinburgh

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Angela Noble (Ms)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 2 288 996
Address
Wellington Square University Offices
OX1 2JD Oxford

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gill Wells (Ms)
FUNDACIO BARCELONABETA BRAIN RESEARCH CENTER
Spain
EU contribution
€ 3 258 316
Address
Calle Wellington 30
08005 Barcelona

See on map

Activity type
Research Organisations
Administrative Contact
Karine Fauria (Dr)
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL
Spain
EU contribution
€ 1 543 976
Address
Calle Velazquez 94 Planta 1
28006 Madrid

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Sandra Pla (Ms)
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 1 551 450
Address
Nobels Vag 5
17177 Stockholm

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Björn Kull (Dr)
STICHTING VUMC
Netherlands
EU contribution
€ 2 758 900
Address
De Boelelaan 1117
1081 HV Amsterdam

See on map

Activity type
Research Organisations
Administrative Contact
- - (-)
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 1 549 830
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Renata Schaeffer (Ms.)
MEDICAL RESEARCH COUNCIL
United Kingdom
EU contribution
€ 134 120
Address
20 Park Crescent
W1B 1AL London

See on map

Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Andrea Wadeson (Mrs.)
BERRY CONSULTANTS LLP
United Kingdom
EU contribution
€ 585 280
Address
Merchant House 5 East Saint Helen Street
OX14 5EG Abingdon

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Shawn Andersson (VP, Operations)
UNIVERSITE DE GENEVE
Switzerland
EU contribution
€ 1 360 350
Address
Rue Du General Dufour 24
1211 Geneve

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Giovanni Battista Frisoni (Prof.)
STICHTING RADBOUD UNIVERSITEIT
Netherlands
EU contribution
€ 84 464
Address
Houtlaan 4
6525 XZ Nijmegen

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Dianne Stephanie Van Houdt (Msc)
CARDIFF UNIVERSITY
United Kingdom
EU contribution
€ 141 100
Address
Newport Road 30 36
CF24 0DE Cardiff

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Keith Sexton (Dr)
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
France
EU contribution
€ 2 122 150
Address
Rue Viguerie 2 Hotel Dieu Saint Jacques
31052 Toulouse Cedex 3

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Sophie Mourgues (Dr)
IQVIA LTD.
United Kingdom
Address
Brook Drive, Green Park
RG2 6UU Reading, Berkshire

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Joseph Milne (Mr.)
ALZHEIMER EUROPE
Luxembourg
EU contribution
€ 277 000
Address
Rue Dicks 14
1417 Luxembourg

See on map

Activity type
Other
Administrative Contact
Jean GEORGES (Ms.)
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 444 936
Address
Dr Molewaterplein 40
3015 GD Rotterdam

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Johan van der Lei (Prof.)
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
France
EU contribution
€ 681 100
Address
3 Avenue Victoria
75000 Paris

See on map

Activity type
Research Organisations
Administrative Contact
Edith BENMANSOUR (Ms)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 186 100
Address
Rue De Tolbiac 101
75654 Paris

See on map

Activity type
Research Organisations
Administrative Contact
Marie Baquet (Madam)
UNIVERSITY OF LEICESTER
United Kingdom
EU contribution
€ 479 800
Address
University Road
LE1 7RH Leicester

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Marie Adams (Mrs)
IXICO TECHNOLOGIES LIMITED
United Kingdom
EU contribution
€ 528 355
Address
4th Floor Griffin Court 15 Long Lane
EC1A 9PN London

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
John Hall (Dr.)
Araclon Biotech S.L.
Spain
Address
Via Hispanidad
50009 Zaragoza

See on map

Administrative Contact
Ian Sherriff (Mr)
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Germany
EU contribution
€ 340 475
Address
Hansastrasse 27c
80686 Munchen

See on map

Activity type
Research Organisations
Administrative Contact
Tobias Rechmann (Mr.)
Eisai Inc
United States
Address
Tice Boulevard
07677 Woodcliff Lake

See on map

Administrative Contact
Sharon M. Dispoto (Senior Director)
SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
France
Address
Pierre Brossolette 1
91380 Chilly Mazarin

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Laurence Mazuranok (Ms.)
NOVARTIS PHARMA AG
Switzerland
Address
Lichtstrasse 35
4056 Basel

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Dieter Christoph Nussher (Mr.)
BOEHRINGER INGELHEIM INTERNATIONALGMBH
Germany
Address
Binger Strasse
55218 Ingelheim

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Stephane Pollentier (Dr..)
ELI LILLY AND COMPANY LTD
United Kingdom
Address
Lilly House Basingview
RG21 4FA Basingstoke

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Birgit Steckel-Hamann (Dr)
H. LUNDBECK AS
Denmark
Address
Ottiliavej 7-9
2500 Valby

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ejner Knud Moltzen (senior director)
TAKEDA DEVELOPMENT CENTRE EUROPE LTD
United Kingdom
Address
Aldwych 61
WC2B 4AE London

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Polyna Khudyakov (Dr)
AC IMMUNE SA
Switzerland
Address
Parc Scientifique Epfl Pse B
1015 Lausanne

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Fabien Monin (CFO)
BIOGEN IDEC LIMITED
United Kingdom
Address
Innovation House 70 Norden Road
SL6 3AY Maidenhead

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Tina Olsson (Ph.D.)
AMGEN
Belgium
Address
Telecomlaan 5-7
1831 Diegem

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Matt Gaunt (Mr)
PFIZER LIMITED
United Kingdom
Address
Ramsgate Road
CT13 9NJ Sandwich

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Olga Krylova (Dr)
UCB BIOPHARMA
Belgium
Address
Allee De La Recherche 60
1070 Bruxelles

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Katharina Angrosch (M.A)
ARIDHIA INFORMATICS LIMITED
United Kingdom
Address
163 Bath Street
G2 4SQ Glasgow

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
David Allan (Mr.)
F. HOFFMANN-LA ROCHE AG
Switzerland
Address
Grenzacherstrasse 124
4070 Basel

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jason Hannon (Dr.)
KLINIKUM DER UNIVERSITAET ZU KOELN
Germany
EU contribution
€ 908 750
Address
Kerpener Strasse 62
50937 Koeln

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Petra Schreiner-Kaub (Ms.)
MERCK SHARP & DOHME CORP
United States
Address
One Merck Drive
08889 Whitehouse Station Nj

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Karen MacNaul (Executive Director)